Iovance Biotherapeutics, INC Form 4 insider transactions

IOVANCE BIOTHERAPEUTICS' Interim CEO and General Counsel, Frederick G. Vogt, acquired 52,086 shares through RSU vesting, with 22,127 shares withheld for taxes.

IOVANCE BIOTHERAPEUTICS' Chief Regulatory Officer, Raj K. Puri, reported the vesting of restricted stock units and subsequent tax-related share disposition.

Iovance Biotherapeutics' Chief Medical Officer, Friedrich Graf Finckenstein, reported changes in his beneficial ownership following the vesting of restricted stock units.

IOVANCE Biotherapeutics Chief Operating Officer Igor Bilinsky reported the vesting of restricted stock units and subsequent share withholding for tax obligations on September 2, 2025.

Iovance Biotherapeutics' Chief Financial Officer, Corleen M. Roche, was granted 450,000 equity awards, comprising stock options and restricted stock units, effective August 6, 2025.

IOVANCE Biotherapeutics, Inc. Director Athena Countouriotis was granted 67,546 deferred restricted stock units (DRSUs) as part of her compensation, aligning her interests with shareholders.

IOVANCE Biotherapeutics Director Ryan D. Maynard was granted 67,546 Deferred Restricted Stock Units (DRSUs) as part of his compensation, aligning his interests with shareholders.

IOVANCE Biotherapeutics, Inc. Director Michael Weiser was granted 67,546 Deferred Restricted Stock Units (DRSUs) on June 13, 2025, as part of the company's equity incentive plan.

IOVANCE Biotherapeutics Director Iain D. Dukes was granted 135,092 Deferred Restricted Stock Units (DRSUs) on June 13, 2025, as part of the company's 2018 Equity Incentive Plan.

IOVANCE BIOTHERAPEUTICS, INC. Director Wendy L. Yarno was granted 67,546 Deferred Restricted Stock Units (DRSUs) as part of her compensation, as disclosed in a recent SEC Form 4 filing.

Daniel Gordon Kirby, Chief Commercial Officer of IOVANCE Biotherapeutics, has acquired 30,000 shares of common stock at $1.84 per share, signaling management confidence.

Raj K. Puri, Chief Regulatory Officer of IOVANCE BIOTHERAPEUTICS, Inc., reported the vesting of 5,469 restricted stock units and the subsequent withholding of 2,467 shares for tax obligations.

Frederick G. Vogt, Interim CEO and General Counsel of IOVANCE BIOTHERAPEUTICS, reported the vesting of 52,085 restricted stock units and the subsequent withholding of 22,127 shares for tax purposes, resulting in a net increase in his direct common stock holdings.

IOVANCE Biotherapeutics' Chief Medical Officer, Friedrich Graf Finckenstein, reported the vesting of restricted stock units and subsequent share withholding for tax purposes.

Iovance Biotherapeutics' Chief Operating Officer, Igor Bilinsky, reported the vesting of 12,305 restricted stock units and the subsequent disposition of 6,250 shares for tax withholding purposes, resulting in a net beneficial ownership of 93,633 common shares.

IOVANCE Biotherapeutics' Chief Financial Officer, Jean-Marc Bellemin, reported the vesting of 8,789 restricted stock units (RSUs) and the subsequent withholding of 4,464 shares for tax purposes on June 2, 2025.

Raj K. Puri, Chief Regulatory Officer of IOVANCE BIOTHERAPEUTICS, Inc., reported an open market purchase of 5,600 shares of common stock on May 23, 2025, increasing his total beneficial ownership to 206,852 shares.

Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, recently purchased 25,000 shares of the company's common stock.

Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.

Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, was granted 187,500 restricted stock units (RSUs) on March 5, 2025, according to a Form 4 filing.

Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, reports the acquisition of 117,190 restricted stock units (RSUs) on March 5, 2025.

Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, acquired 93,750 restricted stock units on March 5, 2025, according to a Form 4 filing with the SEC.

Igor Bilinsky, the Chief Operating Officer of Iovance Biotherapeutics, reported the acquisition of 93,750 restricted stock units (RSUs) on March 5, 2025, according to a Form 4 filing with the SEC.

Jean-Marc Bellemin, CFO of Iovance Biotherapeutics, was granted 93,750 restricted stock units (RSUs) on March 5, 2025, which will vest over three years.

Jean-Marc Bellemin, CFO of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.

Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.

Frederick G. Vogt, Interim CEO & General Counsel of Iovance Biotherapeutics, reports the vesting and tax withholding of restricted stock units.

Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.

Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.

Daniel Gordon Kirby, Chief Commercial Officer of Iovance Biotherapeutics, received stock options, restricted stock units (RSUs), and performance stock units (PSUs) on February 10, 2025.